Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms, Squamous Cell 1Melanoma 1Lymphoma 1Liver Neoplasms 1Hodgkin Disease 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Carboplatin 24Pemetrexed 18Cisplatin 17Paclitaxel 14pembrolizumab 13Gemcitabine 8osimertinib 7durvalumab 6Docetaxel 6Nivolumab 5Erlotinib Hydrochloride 5130-nm albumin-bound paclitaxel 5capmatinib 3brigatinib 3anlotinib 3Gefitinib 3Drug Therapy 3vosaroxin 2volociximab 2sintilimab 2pralsetinib 2ensartinib 2atezolizumab 2aflibercept 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Oncolytic Virotherapy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × advexin × Thoracic × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡